glutathione and ibs Sinisan Alleviates Stress-Induced Intestinal Dysfunction Depressive-like Behaviors in Mice with Irritable Bowel Syndrome by Enhancing the Intestinal Barrier and Modulating Central 5-Hydroxytryptamine Ultra-Processed Food Consumption and Irritable

1 Prokinetic agents Mechanism of action: Stimulate gastrointestinal smooth muscle contraction Enhance vagal-mediated motility Increase acetylcholine release at the myenteric plexus Clinical effect: Improve ruminal contractions Reduce ruminal atony 2 Anti-inflammatory drugs (NSAIDs) Mechanism of action: Inhibition of cyclooxygenase (COX enzymes) Reduction of prostaglandin synthesis Clinical effect: Decrease inflammation around the vagus nerve Reduce neural irritation and pain Improve neural signal transmission 3 Antimicrobial therapy Mechanism of action: Elimination of infectious agents causing: Reticuloperitonitis Perireticular abscesses Thoracic infections Clinical effect: Prevent progression of inflammation Reduce abscess size and secondary pressure on the nerve 4 Electrolytes and metabolic correctors Mechanism of action: Correction of hypocalcemia, hypokalemia, and metabolic alkalosis Restoration of neuromuscular excitability Clinical effect: Improve ruminal muscle responsiveness Enhance vagal nerve signaling 5 Rumen modifiers and transfaunation Mechanism of action: Restore normal rumen microflora Improve fermentation and volatile fatty acid production Clinical effect: Support rumen recovery Enhance motility indirectly via metabolic pathways Key concept Drugs used in vagus nerverelated ruminal disorders do not repair the nerve itself, but act by: Reducing inflammation Enhancing motility Correcting metabolic imbalances Controlling secondary infections #VeterinaryPharmacology #VagalIndigestion #RumenMotility #MechanismOfAction #RuminantMedicine #ClinicalPharmacology To view or add a comment, sign in Delighted to share an interesting paper by my PhD student, Emama, now published in Frontiers in Endocrinology

A quick reference explanation of the tests mentioned below

According to a 2023 phase 2 trial published in The Lancet, combining cagrilintide with semaglutide produced average weight loss of approximately 15 percent over 32 weeks in participants with overweight or obesity

Brain Sciences , 7